Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
775.89 K
Value Traded
4.83 M
Short % Float
25.97%
-1.25%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
650.34 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
448.83 M
Total Shares
102.90 M
Float Shares
69.81 M
Insiders
32.16%
Institutions
57.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
QUIT Catalyst Timeline
Dated clinical, regulatory and corporate events for Achieve Life Sciences, Inc.
Past FDA Catalysts and PDUFA Decisions
How QUIT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 34%
Micro Cap(rank 234 of 687)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytisinicline Small MoleculesNCT07392125 | Vaping Cessation | Phase 3 | NOT YET_RECRUITING | 800 | Sep 30, 2027 | ||||||
| Cytisinicline Small MoleculesCompletedNCT05566288 | Smoking Cessation | Phase 3 | COMPLETED | 2,138 | Dec 23, 2022 | ||||||
| Cytisinicline Small MoleculesCompletedNCT05431387 | Vaping | Phase 2 | COMPLETED | 160 | Feb 28, 2023 | ||||||
| Cytisinicline Small MoleculesCompletedNCT05631938 | Renal Impairment | Phase 1 | COMPLETED | 44 | Sep 4, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every QUIT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in QUIT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in QUIT for Q2 2026. | ||||
Ownership Trends
QUIT Short Interest
Shares sold short, counted twice a month.
25.97%
Short % of Float
of tradable shares sold short
-
Shares Sold Short
-
Days to Cover
trading days of normal volume to buy every short share back
-
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QUIT ranks across every disease it competes in
Competitive Position is a premium feature
See how QUIT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQUIT News
About Achieve Life Sciences, Inc.
BIOPHARMAWATCH ELITE
Trade the next QUIT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime